PMID- 35624320
OWN - NLM
STAT- MEDLINE
DCOM- 20220701
LR  - 20220701
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
VI  - 59
IP  - 8
DP  - 2022 Aug
TI  - Subclinical atherosclerosis associates with diabetic retinopathy incidence: a 
      prospective study.
PG  - 1041-1052
LID - 10.1007/s00592-022-01897-w [doi]
AB  - BACKGROUND: The prospective correlation between subclinical atherosclerosis and 
      diabetic retinopathy (DR) incidence in Chinese patients with type 2 diabetes 
      mellitus (T2DM) remains elusive. METHODS: Prospective data were obtained from 
      2781 patients with diabetes, among whom 1,964 and 2,180 T2DM patients without any 
      and referable DR at baseline, respectively, were included in the analysis. 
      Multivariate analyses were performed using the Cox proportional hazards model. 
      RESULTS: Over a median follow-up of 22.2 months (interquartile range 12.7-27.7), 
      282 (14.36%) and 125 (5.73%) patients developed any and referable DR, 
      respectively. After adjustment for confounders, each standard deviation (SD) 
      increase in brachial-ankle pulse wave velocity (ba-PWV) was associated with 31% 
      (95% confidence interval 1.15-1.50) and 38% (1.14-1.66) higher risks of incident 
      any and referable DR, respectively. Compared with the lowest ba-PWV quartile, the 
      highest ba-PWV quartile had 135% (1.48-3.72) and 293% (1.83-8.44) higher risks of 
      developing any and referable DR, respectively. Per SD increase of pulse pressure 
      (PP) was associated with 22% (1.09-1.38) and 22% (1.02-1.46) higher risks of 
      incident any and referable DR, respectively. The restricted cubic spline models 
      further indicated a significant linear association of baseline subclinical 
      atherosclerosis with referable DR, and a nonlinear association with any DR. In 
      addition, adding the ba-PWV to the prognostic model for DR incidence improved the 
      C-statistic value, the integrated discrimination improvement value, and the net 
      reclassification improvement value (all P < 0.05). CONCLUSIONS: Baseline 
      subclinical atherosclerosis was significantly associated with an increased risk 
      of DR incidence, and elevated ba-PWV independently predicted incident DR in T2DM 
      patients.
CI  - (c) 2022. Springer-Verlag Italia S.r.l., part of Springer Nature.
FAU - Fang, Qianhua
AU  - Fang Q
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Xiang, Minqi
AU  - Xiang M
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Shi, Juan
AU  - Shi J
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Zhou, Yingxia
AU  - Zhou Y
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Peng, Ying
AU  - Peng Y
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Wang, Shujie
AU  - Wang S
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Liu, Cong
AU  - Liu C
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Hong, Jie
AU  - Hong J
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Gu, Weiqiong
AU  - Gu W
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China.
FAU - Wang, Weiqing
AU  - Wang W
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China. wqingw61@163.com.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China. wqingw61@163.com.
FAU - Zhang, Yifei
AU  - Zhang Y
AUID- ORCID: 0000-0003-0272-0602
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine 
      and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China. feifei-a@163.com.
AD  - Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory 
      for Endocrine and Metabolic Diseases of the National Health Commission of the PR 
      China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of 
      Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of 
      Medicine, Shanghai, China. feifei-a@163.com.
LA  - eng
GR  - DMRFP_II_01/SHMHDF/
GR  - 2016YFC0901200/National Key Research and Development Program of China/
GR  - 2018YFC1311800/National Key Research and Development Program of China/
GR  - 2018YFC1314800/National Key Research and Development Program of China/
GR  - 2019LJ07/Program of Shanghai Academic Research Leader/
PT  - Journal Article
DEP - 20220527
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
SB  - IM
MH  - Ankle Brachial Index/adverse effects
MH  - *Atherosclerosis/complications/epidemiology
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - *Diabetic Retinopathy/diagnosis/epidemiology/etiology
MH  - Humans
MH  - Prospective Studies
MH  - Pulse Wave Analysis/adverse effects
MH  - Risk Factors
OTO - NOTNLM
OT  - Brachial-ankle pulse wave velocity
OT  - Diabetic retinopathy
OT  - Pulse pressure
OT  - Subclinical atherosclerosis
OT  - Type 2 diabetes mellitus
EDAT- 2022/05/28 06:00
MHDA- 2022/07/02 06:00
CRDT- 2022/05/27 23:26
PHST- 2022/02/03 00:00 [received]
PHST- 2022/04/14 00:00 [accepted]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/07/02 06:00 [medline]
PHST- 2022/05/27 23:26 [entrez]
AID - 10.1007/s00592-022-01897-w [pii]
AID - 10.1007/s00592-022-01897-w [doi]
PST - ppublish
SO  - Acta Diabetol. 2022 Aug;59(8):1041-1052. doi: 10.1007/s00592-022-01897-w. Epub 
      2022 May 27.